Skip to content

PHARMA SERVICES

Absorbed by GESTIFAR KBO/BCE: BE 0471.348.140 subsidiary of ETABLISSEMENT VANDERELST SRL

Timeline

32 events since 2000
2022
Merger: absorbed by GESTIFARDissolution of the company · Dissolved without liquidation · General meeting of 17-06-20222 points ▸
  • General meeting, 17-06-2022
  • Accounting effect, 01-01-2022
  • The deed holds 8 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2021 filed PDFfull format · 33 days before the deadline
2021
Annual accounts 2020 filed PDFfull format · 19 days late
Merger proposal: to be absorbed by GestifarCapital from €61,973.38 to €218,038.77, 630 new shares · Permanent representative: Jean-Christophe Vanderelst · Legal-form conversion: from public limited company to private limited company11 points ▸
  • Accounting effect, 01-01-2021
  • Legal-form conversion, from public limited company to private limited company, mentioned twice in the deed
  • Capital, €62,000, 1,251 shares
  • Founding capital, €31,011.48, 1,251 shares
  • Capital increase, €30,988.52
  • Capital, €18,550, 880 shares
  • Founding capital, €61,973.38, 250 shares
  • Capital increase, €156,065.39
  • Capital decrease, €108,038.77
  • Capital decrease, €91,450
  • Permanent representative, Jean-Christophe Vanderelst
  • The deed holds 11 more points.

Open the deed in the Belgian Official Gazette

2020
Annual accounts 2019 filed PDFfull format · 35 days late
2019
Annual accounts 2018 filed PDFmicro format · 8 days before the deadline
2018
Liquidity more than quadruples current ratio 9.14 The current ratio rises from 1.88 to 9.14. Short-term debt falls from €99,937 to €12,043.
Annual accounts 2017 filed PDFmicro format · 23 days late
2017
Annual accounts 2016 filed PDFmicro format · 18 days late
2016
Liquidity more than doubled current ratio 20.36 The current ratio rises from 7.69 to 20.36. Short-term debt falls from €21,962 to €8,709.
Equity above €150,000 equity €168,614 ▲14.7% After 5 profitable years in a row, equity reaches €168,614.
Annual accounts 2015 filed PDFfull format · 23 days late
2015
Highest result from 2007 to 2021 net €36,962 ▲1,075% The operating result of €37,128 and the net result of €36,962 are both a record.
Annual accounts 2014 filed PDFfull format · 44 days before the deadline
2014
Annual accounts 2013 filed PDFfull format · 43 days before the deadline
2013
Equity above €100,000 equity €107,119 ▲12% After 2 profitable years in a row, equity reaches €107,119.
Annual accounts 2012 filed PDFfull format · 34 days before the deadline
2012
Back to profit net €21,090 The net result is €21,090, after one loss-making year.
Annual accounts 2011 filed PDFfull format · 19 days before the deadline
2011
Weakest financial year net -€20,174 The net result drops to -€20,174, the lowest from 2007 to 2021.
Annual accounts 2010 filed PDFfull format · 1 day late
2010
Annual accounts 2009 filed PDFfull format · 30 days late
2009
Back to profit net €15,811 The net result is €15,811, after one loss-making year.
Annual accounts 2008 filed PDFfull format · 18 days late
2008
Annual accounts 2007 filed PDFfull format · 23 days before the deadline
2007
Annual accounts 2006 filed PDFfull format · 26 days late
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2003
Annual accounts 2003 filed PDFfull format
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2000
Incorporation 21 publications in the Belgian Official Gazette, the last on 14-07-2022

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

A capital increase in 2021 brought the capital to €218,039.1 PHARMA SERVICES has filed 21 sets of annual accounts, the latest for financial year 2021.2 In 2022 the company was absorbed by merger into GESTIFAR.3

  1. 1Belgian Official Gazette, 01-07-2021
  2. 2National Bank, annual accounts 2021
  3. 3Belgian Official Gazette, 14-07-2022